Greenwich Investment Management’s AbbVie ABBV Stock Holding History

Greenwich Investment Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,457	Closed	-$265K	–	38
2024 Q1	$265K	Hold	1,457	–	–	0.21%	31
2023 Q4	$226K	Hold	1,457	–	–	0.17%	35
2023 Q3	$217K	Buy	+1,457	New	+$214K	0.17%	38
2023 Q2	–	Sell	-1,457	Closed	-$232K	–	47
2023 Q1	$232K	Hold	1,457	–	–	0.18%	42
2022 Q4	$235K	Sell	1,457 -415	-22%	-$63.6K	0.19%	38
2022 Q3	$251K	Sell	1,872 -1,000	-35%	-$143K	0.2%	43
2022 Q2	$440K	Hold	2,872	–	–	0.32%	37
2022 Q1	$466K	Sell	2,872 -60	-2%	-$8.72K	0.28%	40
2021 Q4	$397K	Buy	+2,932	New	+$346K	0.27%	46
2020 Q3	$252K	Hold	2,872	–	–	0.28%	38
2020 Q2	$282K	Hold	2,872	–	–	0.36%	39
2020 Q1	$219K	Sell	2,872 -50	-2%	-$4.26K	0.27%	42
2019 Q4	$259K	Buy	+2,922	New	+$243K	0.25%	49
2019 Q1	–	Sell	-2,246	Closed	-$207K	–	63
2018 Q4	$207K	Hold	2,246	–	–	0.25%	54
2018 Q3	$212K	Hold	2,246	–	–	0.23%	54
2018 Q2	$208K	Hold	2,246	–	–	0.21%	57
2018 Q1	$213K	Hold	2,246	–	–	0.25%	54
2017 Q4	$217K	Buy	+2,246	New	+$212K	0.31%	46

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Greenwich Investment Management's ABBV Position: Q2 2024 in Review

Greenwich Investment Management sold out of AbbVie (ABBV) in Q2 2024, closing a stake of 1,457 shares — an estimated $265K sold.

Greenwich Investment Management first reported a position in ABBV in Q4 2017 and held it in 18 quarters. The position peaked at $466K in Q1 2022. 3,365 funds tracked by Wall St. Rank hold ABBV as of Q2 2024.

Greenwich Investment Management reported no remaining AbbVie position as of Q2 2024 after selling out during the quarter.
Greenwich Investment Management sold 1,457 AbbVie shares in Q2 2024, an estimated $265K.
Greenwich Investment Management first reported a position in AbbVie in Q4 2017 and held it in 18 quarters.
Greenwich Investment Management's AbbVie position peaked at $466K in Q1 2022.
3,365 funds tracked by Wall St. Rank held AbbVie as of Q2 2024.

Based on Greenwich Investment Management's 13F filing for Q2 2024, filed 14 Aug 2024.